Все публикации

Background Methods Results Conclusion

The purpose of this investigation was to formulate and evaluate a chemically optimized [225Ac]Ac-labeled radioimmunoconjugate targeting the insulin-like growth factor-2 receptor (IGF2R) for targeted alpha therapy of osteosarcoma, a disease with unchanging survival rates for over 40 years. The anti-I

PSMA-targeted radioligand therapy is a promising approach for the treatment of advanced prostate cancer; however, the clinical efficacy of [177Lu]Lu-PSMA-617 (Pluvicto®) is limited by the relatively low cytotoxic potency of the β-emitting radionuclide 177Lu (t1/2: 6.65 d). This has driven high inter

Background Results Conclusions

Ученые и врачи обсудили последние достижения в диагностике и лечении злокачественных новообразований кожи